Reference Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Ref Type
PMID
Authors E. Lew, C. Walsh, E. Martin, A. Albert, G.G. Li, Y. Yokoyama
Title Immuno-oncologic efficacy of RXDX-106, a selective, TAM family small molecule kinase inhibitor
Journal European Journal of Cancer
Vol 69
Issue
Date December 2016
URL http://www.sciencedirect.com/science/article/pii/S0959804916326739?via%3Dihub
Abstract Text European Journal of Cancer, Vol 69, Supplement 1, December 2016, Page S31

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
RXDX-106 RXDX-106 1 0
Drug Name Trade Name Synonyms Drug Classes Drug Description
RXDX-106 CEP-40783 AXL Inhibitor 27 MERTK Inhibitor 9 MET Inhibitor 51 TYRO3 Inhibitor 8 RXDX-106 is a small molecule inhibitor of TAM family kinases (Axl, Mertk, and Tyro3) and Met that promotes anti-tumor immune response, resulting in tumor growth inhibition (Eur J Cancer, Vol 69, Supplement 1, December 2016, Page S31, PMID: 30501104).
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown breast carcinoma not applicable RXDX-106 + unspecified PD-1 antibody Preclinical Actionable In a preclinical study, RXDX-106 in combination with an unspecified anti-PD-1 antibody resulted in near complete regression in orthotopic animal models of breast carcinoma (Eur J Cancer, Vol 69, Supplement 1, December 2016, Page S31). detail...
Unknown unknown breast carcinoma not applicable RXDX-106 Preclinical Actionable In a preclinical study, RXDX-106 inhibited tumor growth in orthotopic animal models of breast carcinoma (Eur J Cancer, Vol 69, Supplement 1, December 2016, Page S31). detail...